A Study to Evaluate the Effect of Different Meal Types on the Pharmacokinetics of DBPR108 in Healthy Subjects

Phase 1 Completed 21 enrolled CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

RandomizedCrossoverOpen-labelTreatment

Summary

This is an open-label, randomized, three-period, crossover, single-dose study to evaluate the effects of a low-fat meal and a standard meal on the pharmacokinetics of DBPR108 and the safety and tolerability of DBPR108 under different fed states in healthy adult subjects.

Timeline

Start: 2022-05-29
Primary completion: 2022-06-07
Completion: 2022-07-14

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	DBPR108	Small molecule	100 mg	Oral

Indications

No indication recorded.